Paris, France, January 22, 2026 – PulseSight Therapeutics SAS, an ophthalmology clinical stage biotech company developing disruptive vectorized gene therapies with minimally-invasive delivery technology, is pleased to announce the completion of PST-611 phase I clinical trial enrolment. Trial data will be … Read More
PARIS, Feb. 13, 2025 (GLOBE NEWSWIRE) — PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, today announces the first close of its Series A financing with existing investor Pureos BioVentures committing new … Read More
PARIS, Oct. 07, 2024 (GLOBE NEWSWIRE) — PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, is pleased to confirm that it will be presenting data on its lead program PST-611, expressing human … Read More